A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2015
At a glance
- Drugs MVA-HIV62 (Primary) ; PGA2-JS7 (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Adverse reactions
- Sponsors GeoVax Labs
- 10 Jun 2017 Biomarkers information updated
- 13 Aug 2015 Last checked against ClinicalTrials.gov record.
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.